| DIRECT COMPETITOR COMPARISON | |
| INFI | BIIB | BMY | PFE | Industry | | Market Cap: | 149.59M | 13.70B | 49.84B | 150.42B | 59.20M | | Employees: | 161 | 4,700 | 35,000 | 81,800 | 56 | | Qtrly Rev Growth (yoy): | 451.00% | 2.50% | 4.40% | -2.90% | 18.90% | | Revenue (ttm): | 103.42M | 4.32B | 21.14B | 45.82B | 12.73M | | Gross Margin (ttm): | 25.73% | 91.12% | 72.39% | 86.61% | 50.63% | | EBITDA (ttm): | 7.47M | 1.68B | 6.32B | 21.31B | -1.76M | | Oper Margins (ttm): | 5.25% | 28.43% | 26.65% | 37.42% | -19.80% | | Net Income (ttm): | 22.17M | 869.75M | 3.79B | 8.09B | N/A | | EPS (ttm): | 0.869 | 2.988 | 1.933 | 1.204 | N/A | | P/E (ttm): | 6.57 | 15.86 | 13.02 | 15.48 | 24.20 | | PEG (5 yr expected): | N/A | 1.39 | 4.54 | 6.03 | 1.33 | | P/S (ttm): | 1.45 | 3.17 | 2.36 | 3.28 | 3.00 |
|
| BIIB = Biogen Idec Inc. | | BMY = Bristol-Myers Squibb Co. | | PFE = Pfizer Inc. | | Industry = Diagnostic Substances | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.55 | 0.00% | 57.24B | 12.33 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.38 | 0.00% | 13.70B | 15.86 | | Genzyme Corp. | GENZ | 50.27 | 0.00% | 13.34B | 28.66 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.26 | 0.00% | 41.63B | 17.89 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.25 | 0.00% | 8.96B | 1025.51 | | Teva Pharmaceutical Industries Limited | TEVA | 53.57 | 0.00% | 47.20B | 49.01 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.29 | 0.00% | 3.96B | 19.22 | | King Pharmaceuticals Inc. | KG | 11.67 | 0.00% | 2.90B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.20 | 0.00% | 5.56B | 111.66 | | Pfizer Inc. | PFE | 18.64 | 0.00% | 150.42B | 15.48 | | Johnson & Johnson | JNJ | 64.16 | 0.00% | 177.02B | 14.01 | | GlaxoSmithKline plc | GSK | 42.44 | 0.00% | 107.59B | 13.35 | | Sanofi-Aventis | SNY | 39.52 | 0.00% | 103.19B | N/A | | Novartis AG | NVS | 55.78 | 0.00% | 126.69B | 16.70 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.85 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.62 | 0.00% | 66.15B | 9.16 | | Abbott Laboratories | ABT | 54.24 | 0.00% | 83.90B | 14.70 | | Bristol-Myers Squibb Co. | BMY | 25.16 | 0.00% | 49.84B | 13.02 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|